导师姓名： 陆舜 专业代码： 100214
性别： 男 专业名称： 肿瘤学
培养单位： 附属胸科医院 三级学科/
专业领域：
导师类型： 博士生导师 专业学位导师： 兼
联系方式：
邮编： 邮箱地址： shun_lu@hotmail.com

研究方向 (点击浏览详细信息)
肺癌的靶向治疗与免疫治疗

社会任职
亚洲代表曾担任美国临床肿瘤学会（ASCO）国际事务部委员；目前担任ASCO多学科诊治小组（MCMC）成员、国际肺癌研究会（IASLC）组织委员会委员；国际肺癌研究会官方杂志Journal of Thoracic Oncology副主编；Lung Cancer副主编；The Oncologist杂志编委；担任国家智库成员：国家卫建委规范化用药专家委员会肿瘤药物组成员兼胸部肿瘤组长、国家卫建委抗肿瘤新药专家组委员、国家卫建委肺癌临床路径专家组成员、国家食品药品监督管理局新药评审专家；协会职务：中国抗癌协会肺癌专业委员会主任委员、中华医学会肿瘤学会委员、中华医学会肿瘤学会内科专家组成员兼胸部肿瘤组组长、中国临床肿瘤学会（CSCO）常务理事、希斯科基金会副理事长，中国医药教育协会肿瘤免疫治疗专业委员会主任委员、中国医药生物技术协会副主任委员，CSCO肿瘤相关性贫血委员会副主任委员，CSCO脑转移癌专家委员会副主任委员，中国控制吸烟协会控烟与肺癌防治专业委员会副主任委员，CSCO肿瘤生物标志物委员会常务委员，CSCO医药研究和安全评价专家委员会委员，CSCO癌症与康复治疗委员会常务委员，中国医师协会临床精疗医学专业委员会委员，中国抗癌协会姑息治疗委员会委员，中国肿瘤驱动基因分析联盟执行委员会常委，国家自然科学基金评审委员会委员，吴阶平医学基金会肿瘤学部常委，吴阶平医学基金会肿瘤多学科（MDT）专业委员会主任委员，上海市医学会肿瘤学会主任委员、上海市医学会理事、上海市医师协会肿瘤科分会副会长、肿瘤内科规培组长等，上海市抗癌协会理事、上海市抗癌协会姑息治疗委员会副主任委员、上海市抗癌协会免疫治疗委员会主任委员、广东省临床试验协会第二届理事会副会长；同时担任上海市医学类高级职称内Ⅱ组评审委员、上海市干部保健专家库成员、上海市医学会医疗事故技术鉴定专家库成员、上海市化疗质控中心委员、上海市控烟协会理事、上海市青联委员、徐汇区政协委员。获2013年作为第1负责人获得上海市医学科技奖三等奖。2017年获得上海市抗癌协会二等奖；2018年获得中国抗癌协会三等奖。2018年获得仁心医者?上海市杰出专科医师提名奖。2019年获上海市科学技术一等奖。

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
YJXT** 肺癌多学科联合诊疗技术的临床应用研究 上海市胸科医院协同创新项目立项（重大项目） 2019-01~2021-12 200万元 课题负责人
2018ZX**-001-003 SPH1188-11临床试验II期 国家科技重大专项项目重大新药创制 2018-01~2020-12 120万元 子课题负责人
重大癌症分子分型和诊疗疗效跟踪管理平台 2016年上海市信息化发展专项资金项目 2017-09~2018-08 87万元 课题负责人
** 创新抗肿瘤EGFR-TKI药物SPH1188-11的IIa期临床研究 上海市2017年度“科技创新行动计划”生物医药领域科技支撑项目 2017-06~2020-09 24.5万元 课题负责人
** 外泌体miRNAs介导FGFR/GLI2信号通路调控肺鳞癌干细胞表型及侵袭转移的分子机制 国家自然基金面上项目 2017-01~2020-12 60万元 课题负责人
2016YFC** 基于组学特征的肺癌免疫治疗疗效预测指标的构建和验证 科技部“重大慢性非传染性疾病防控研究”重点专项 2017-01~2020-12 980万元 课题负责人
** 靶向药物耐药的中国肺癌人源肿瘤移植模型的建立及应用 上海市科研计划项目-实验动物研究领域科技支撑项目 2014-10~2016-09 10万元 课题负责人
13XD** 肺鳞癌FGFR/Ras/Raf靶向治疗的转化性研究 2013年度上海市优秀学术带头人计划 2013-07~2015-06 40万元 课题负责人
S2012GR0035 中瑞合作肺癌临床医学中心肺癌诊治关键技术转化医学研究 国家科技部国际合作课题 2013-01~2015-12 250万元 课题负责人
2012AA02A502 肺癌的分子分型和个体化诊疗 国家863重大课题子课题 2013-01~2015-12 20万元 课题负责人
YG2012ZD05 靶向FGFR/Ras/Raf信号通路的肺鳞癌治疗策略的转化研究 上海交通大学多学科交叉项目培育重点项目（医工） 2013-01~2015-12 50万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, Zheng H, Yao C, Wang Y, Lu S （通讯作者） The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC J Thorac Oncol 2019 14(8):1378-1389
Chen R, Yang X, Ding Z, Zhu L, Lu S （通讯作者）, Yu Y Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes Eur J Surg Oncol 2019 45(5):838-844
Yu Y, Zhang Q, Zhang J, Lu S （通讯作者） Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study J Cancer Res Ther 2019 15(4):909-913
Yongfeng Yu, Qiuxiang Ou, Xue Wu, Hairong Bao, Yan Ding, Yang W. Shao, Shun Lu （通讯作者） Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer Lung Cancer 2019 127:19-24
Zhou Z, Zhao Y, Shen S, Gu L, Niu X, Xu Y, Zhang T, Xiang J, Mao X, Lu S （通讯作者） Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors J Thorac Oncol 2019 14(8):e157-e159
Yang Y, Li Z, Yuan H, Ji W, Wang K, Lu T, Yu Y, Zeng Q, Li F, Xia W, Lu S （通讯作者） Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer Oncogenesis 2019 8(9):50
Chen Z, Shen S, Shi W, Jiang G, Wang X, Jian H, Zhou Z, Ding Z, Lu S （通讯作者） Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study Cancer Manag Res. 2019 11:6543-6552
Li Z, Wang Z, Tang Y, Lu X, Chen J, Dong Y, Wu B, Wang C, Yang L, Guo Z, Xue M, Lu S （通讯作者）, Wei W, Shi Q Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics Nature Communication 2019 10(1):3856.
Shun Lu （通讯作者）,Wei Li, Caicun Zhou, Cheng-ping Hu, Shukui Qin, Gang Cheng, Jifeng Feng, Jie Wang, Agnieszka Cseh, Barbra Peil, Neil Gibson, Eva Ehrnrooth, Li Zhang. Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung Onco Targets Therapy 2018 30;11:8565-8573
Kaixuan Wang, Wenxiang Ji, Yongfeng Yu, Ziming Li, Xiaomin Niu, Weiliang Xia, Shun Lu （通讯作者） FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer Oncogene 2018 37(39):5340-5354
Shun Lu, Yongfeng Yu, Shijun Fu, Hongye Ren. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China PLoS One 2018 Oct23;12(10)
Xinghao Ai, Xiaomin Niu, Lianpeng Chang, Rongrong Chen, Sai-HOng Ignatius Ou, Shun LU （通讯作者） Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient Lung Cancer 2018 123:83-86
Yunhua Xu, Feifei Zhang, Xiaoqing Pan, Guan Wang, Lei Zhu, Jie Zhang, Danyi Wen, Shun Lu （通讯作者） Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance Cancer Commun (Lond). 2018 9;38(1):19
Tingting Lu, Ziming Li, Ying Yang, Wenxiang Ji, Yongfeng Yu, Xiaomin Niu, Qingyu Zeng, Weiliang Xia, Shun Lu （通讯作者） The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018 1;423:36-46
Shun Lu,Zhiwei Chen,Chengping Hu,Jian Zhang,Yuan Chen,Yong Song,Qiong Zhao,Yun Fan,Gang Wu,Zhiyong Ma,Jian Fang,Qitao Yu,Zhe Liu Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial Journal of Thoracic Oncology 2018 13(11):1743-1749
Li Ziming, Shen Lan, Ding Ding, Huang Jia, Zhang Jie, Chen Zhiwei, Lu Shun. （通讯作者） Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol 2018 Jul;13(7):987-995
Xinghao Ai, Feng Mao, Shengping Shen, Yang Shentu, Jiejun Wang, Shun Lu （通讯作者） Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway BMC Cancer. 2018 11;18(1):407
Yunhua Xu, Xia Song, Fangmin Du, Qiong Zhao, Li Liu, Zhiyong Ma, Shun Lu （通讯作者） A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer Journal of Cancer 2018 9(24):4718-4725
Zhen Zhou, Yi Zhao, Lingping Gu, Xiaomin Niu, Shun Lu （通讯作者） Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10 Mol Med Rep. 2018 17(2):2153-2160
Shun Lu （通讯作者）, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua, Weiguo Su Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non?Small-Cell Lung Cancer Journal of Clinical Oncology 2018 36(12):1207-1217
Xiaomin Niu, Fatao Liu, Yi Zhou, Zhen Zhou, Daizhan Zhou, Ting Wang, Ziming Li, Xiangyun Ye, Yongfeng Yu, Xiaoling Weng, Hong Zhang, Junyi Ye, Meilin Liao, Yun Liu, Zhiwei Chen, Shun Lu （通讯作者） Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment Clinical Cancer Research 2017 1;23(17):5003-5014
H.Nokihara, Shun Lu （共同第一作者）, Tony S.K.Mok, K.Nakagawa, N.Yamaoto, Y.K.Shi, L.Zhang, R.A.Soo, J.C.Yang, S.Sugawara, M.Nishio, T.Takahashi, K.Goto, J.Chang, M.Maemondo, Y.Ichinose, Y.Cheng, W.T.Lim, S.Morita, T.Tamura Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Annals of Oncology 2017 1;28(11):2698-2706
Yingjia Sun, Xinghao Ai, Jingwen Hou, Xiangyun Ye, Ruijun Liu, Shengping Shen, Ziming Li, Shun Lu （通讯作者） Integrated discovery of FOXO1–DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer Molecular BioSystems 2017 13(2):330-337
Xiangyun Ye, Jia Wei, Ziming Li, Xiaomin Niu, Jiemin Wang, Yunqin Chen, Zongming Guo, Shun Lu （通讯作者） Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry Oncotarget 2017 17; 8(3): 5487–5497
Yi Zhao, Yi Yang, Yunhua Xu, Shun Lu （通讯作者）, Hong Jian AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling FEBS Open Bio 2017 7(4):472-476
Yin Tang, Zhuo Wang, Ziming Li, Jungwoo Kim, Yuliang Deng, Yan Li, James R.Heath, Wei Wei, Shun Lu （通讯作者）, Qihui Shi High-throughput screening of rare metabolically active tumor cells in pleural effusion andperipheral blood of lung cancer patients. Proc Natl Acad Sci U S A. 2017 114(10):2544-2549.
Yi Yang, Baijun Cheng, Shun Lu （通讯作者） Thrombomodulin regulates doxorubicin sensitivity through epithelial-mesenchymal transition in non-small cell lung cancer European Review for Medical and Pharmacological Sciences 2017 21(1):95-101
Yi Yang, Baijun Cheng, Hong Jian, Zhiwei Chen, Yi Zhao, Yongfeng Yu, Ziming Li, Meilin Liao, Shun Lu （通讯作者） XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D culture Am J Transl Res 2017 9(2):700-707
Rongrong Chen, Zhengping Ding, Lei Zhu, Shun Lu （通讯作者）,Yongfeng Yu Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification European Journal of Surgical Oncology 2017 43(12):2308-2314
Zhiwei Chen, Qingquan Luo, Zhen Zhou, Hong Jian, Shun Lu （通讯作者）, Meilin Liao Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression Oncotarget 2017 8(45):79703-79711
Jingqi Zhuang, Yongfeng Yu, Ziming Li, Shun Lu （通讯作者） Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis Oncotarget 2017 25;8(32):53675-53683
Xiangyun Ye, Xiaomin Niu, Linping Gu, Yunhua Xu, Ziming Li, Yongfeng Yu, Zhiwei Chen, Shun Lu （通讯作者） Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth Oncotarget. 2017 24;8(4):6984-6993
Xiangyun Ye, Jia Wei, Ziming Li, Xiaomin Niu, Jiemin Wang, Yunqin Chen, Zongming Guo, Shun Lu （通讯作者） Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry. oncotarget 2017 8(3):5487-5497
Hong Jian, Wei Li, Zhiyong Ma,Jianjin Huang,Jifeng Feng, Yong Song, Beili Gao, Huili Zhu, Min Tao,Chong Bai,Shenglin Ma, HOngming Pan, Shukui Qin, Dong Hua, Yongfeng Yu, Shun Lu （通讯作者） Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Scientific Reports 2017 16;7(1):8483
Hong Yuan, Ziming Li, Jiaxiang Shao, Wenxiang Ji, Weiliang Xia, Shun Lu （通讯作者） FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. Journal of Experimental and clinical cancer research 2017 30;36(1):72
Qiang Tan, Fan Li, Guan Wang, Weiliang Xia, Ziming Li, Xiaomin Niu, Wenxiang Ji, Hong Yuan, Qiang Xu,Qingquan Luo, Jie Zhang, Shun Lu （通讯作者） Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in chinese smoking patients Oncotarget 2016 7(14):18394-18402
Yongfeng Yu, Hong Jian, Lan Shen, Lei Zhu, Shun Lu （通讯作者） Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases Eur J Surg Oncol. 2016 2016 ;42(11):1714-1719
Yongfeng Yu, Zhengping Ding, Hong Jian, Lan Shen, Lei Zhu, Shun Lu （通讯作者） Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma Cancer Medicine 2016 5(9):2323-2331
Shun Lu, Jie Zhang, Ming Ye, Baoai Wang, Bin Wu Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer Pharmacogenomics 2016 17(9):985-994
Ziming Li, Jia Huang, Hong Yuan, Zhiwei Chen, Qingquan Luo, Shun Lu （通讯作者） SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation Oncotarget. 2016 2016;7(14):18927-39
Shun Lu, Ying Cheng, Caicun Zhou, Jie Wang, James Chih-Hsin Yang, Ping-hai Zhang, Xiao-qing Zhang, Xin Wang, Mauro Orlando, Yilong Wu Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer Clinical Lung Cancer 2016 17(5):e103-e112
Wenxiang Ji,Yongfeng Yu,Ziming Li,Guan Wang,Fan Li,Weiliang Xia,Shun Lu （通讯作者） FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the hedgehog pathway Oncotarget 2016 2016 ;7(12):15118-34.
Yongfeng Yu, Zhengping Ding, Lei Zhu, Haohua Teng, Shun Lu （通讯作者） Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases SpringerPlus 2016 5(1):894
Xiangyun Ye, Yingjia Sun, Yunhua Xu, Zhiwei Chen, Shun Lu （通讯作者） Integrated in silico-in vitro discovery of lung cancer-related tumor pyruvate kinase M2 (PKM2) inhibitors Medicinal Chemistry 2016 12(7):613-620
Xiangyun Ye, Qingquan Luo,Yunhua Xu, Naiwang Tang, Xiaomin Niu, Ziming Li, Shengping Shen, Shun Lu （通讯作者）, Zhiwei Chen 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway J Cell Mol Med. 2015 2015;19(3):651-63
Zhen Zhou, Xiaomin Niu, Chuanjia Li,Shengping Shen, Shun Lu （通讯作者） Inhibition of the growth of non-small cell lung cancer by miRNA-1271 Am J Transl Res. 2015 2015 ;7(10):1917-24
Shun Lu （通讯作者）, Lu Li, Yi Luo, Li Zhang, Gang Wu, Zhiwei Chen, Cheng Huang, Shuliang Guo, Yiping Zhang, Xiangqun Song, Yongfeng Yu, Caicun Zhou, Wei Li, Meilin Liao, Baolan Li, Liyan Xu, Ping Chen, Chunhong Hu, Chengping Hu A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer Journal of Thoracic Oncology 2015 2015;10(1):206-11.
Xinghao Ai, Shengping Shen, Lan Shen, Shun Lu （通讯作者） An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer Biochimie. 2015 2015 ;112:111-120
Yunhua Xu,Shun Lu （通讯作者） Regulation of β-catenin-mediated esophageal cancer growth and invasion by miR-214 Am J Transl Res. 2015 2015;7(11):2316-25
Shun Lu （通讯作者）, Yongfeng Yu, Zhiwei Chen, Xiangyun Ye, Ziming Li, Xiaomin Niu Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies Lung. 2015 2015;193(5):805-14.
Yunhua Xu, Shun Lu （通讯作者） Transforming growth factor-β1-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line Mol Med Rep 2015 2015 ;11(1):417-21.
Yingjia Sun, Xinghao Ai, Shengping Shen, Lingping Gu, Shun Lu （通讯作者） Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases Patient Prefer Adherence. 2015 2015 ;9:1165-9.
Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X, Yu Y, Zhou C, Li W, Liao M, Li B, Xu L, Chen P, Hu C, Hu C A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer J Thorac Oncol. 2015 10(1):206-211
Sun Y, Ai X, Shen S, Lu S. （通讯作者） NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10 Oncotarget. 2015 2015;6(10):8244-54.
Yu Y, Song Z, Yang S, Yang X, Zhang J, Lu S （通讯作者） Everolimus and zoledronic acid—a potential synergistic treatment for lung adenocarcinoma bone metastasis Acta Biochim Biophys Sin 2014 2014 ;46:792-801.
Ding D, Yu Y, Li Z, Niu X, Lu S. （通讯作者） The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. Onco Targets Ther 2014 2014;7:387-93
Ai X, Sun Y, Wang H, Lu S （通讯作者） A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity Amino Acids. 2014 2014 ;46:1635-48.
Jian H, Zhao Y, Liu B, Lu S （通讯作者） SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014 2014;35:11051-6
Li Z, Xu L, Tang N, Xu Y, Ye X, Shen S, Niu X, Lu S （通讯作者） The polycomb group protein EZH2 inhibits lung cancer cell growth 4 by repressing the transcription factor Nrf2. FEBS Lett. 2014 2014 ;588:3000-7
Chen Z, Ye X, Tang N, Shen S, Li Z, Niu X, Lu S （通讯作者） The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer Br J Pharmacol. 2014 2014;171:3196-211
Yang Y, Zhao Y, Ai X, Cheng B, Lu S （通讯作者） Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. Int J Clin Exp Pathol. 2014 2014 ;7:8453-61
Chen Z, Ye X, Tang N, Shen S, Li Z, Niu X, Lu S （通讯作者）, Xu L The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer. Br J Pharmacol 2014 2014 ;171:3196-211
Tan Q, Wang G, Huang J, Shun L. （通讯作者） Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking OncoTargets and Therapy 2013 2013,21:1471-9
Shen S, Ai X, Lu S （通讯作者） Long-term survival in thymic epithelial tumors: A single-center experience from China J Surg Oncol 2013 2013,107:167-172
Li ZM, Xie QR, Chen Z,Lu S. （通讯作者） Regulation of SIRT2 Levels for Human Non-Small Cell Lung Cancer Therapy Lung Cancer. 2013 2013 ;82:9-15
Xu Y, Lu S （通讯作者） Metformin inhibits esophagus cancer proliferation through upregulation of USP7 Cell Physiol Biochem. 2013 2013;32:1178-86
Chen Z, Xu L, Ye X, Lu S. （通讯作者） Polymorphisms of microRNA sequences or binding sites and lung cancer: a meta-analysis and systematic review PLoS One 2013 2013;8:e61008
Zi-Ming Li,Zheng-Ping Ding, Qing-Quan Luo, Shun Lu. （通讯作者） Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer Chest 2013 2013 ;144:1253-60
Chen Z, Luo Q, Jian H, Shun Lu. （通讯作者） Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer Onco Targets Ther 2013 2013 ;6:645-50
Niu X, Li H, Chen Z,Lu Shun （通讯作者） A Study of Ethnic Differences in TGFβ1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Non-Small-Cell Lung Cancer J Thorac Oncol. 2012 2012 ;7:1668-75
Zheng Y, Kan M, Yu L, Niu X, Zhou D, He L, Lu S （通讯作者） GPC5 rs** Polymorphism and Risk of Lung Cancer in Han Chinese. Cancer Invest 2012 2012 ; 30:13-9
Shen L, Li Z, Shen S, Lu Shun （通讯作者） The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines Lung Cancer 2012 2012 ;78:193-200
Yang Y, Zhou Z, Niu XM, Shun L （通讯作者） Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients J Surg Oncol. 2012 2012 ;106:736-41
Yu Y, Song Z, Gao H, Shun Lu （通讯作者） EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma J Cancer Res Clin Oncol. 2012 2012 ;138:1421-5
Yongfeng Yu, Zhengbo Song, Shun Lu （通讯作者） Chinese Pediatric and Adolescent Primary Tracheobronchial Tumors:a Hospital- Based Study Pediatr Surg Int. 2011 2011 ;27:721-6.
SONG Zheng-bo, YU Yong-feng, CHEN Zhi-wei and LU Shun Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. Chinese Medical Journal 2011 2011; 124: 2279 -2283
Zhengbo Song, Yongfeng Yu, Shun Lu （通讯作者） Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: Feasible Drugs for Feasible Patients. Med Oncol. 2011 2011 ;28 Suppl 1:S605-12
Zhiwei Chen, Ziming Li, Xiaomin Niu, Xiangyun Ye, Yongfeng Yu, Shun Lu （通讯作者） The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case–control studies Mutagenesis. 2011 2011 ;26:437-46
Xiaomin Niu, Zhiwei Chen, Shengping Shen,Shun Lu （通讯作者） Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population. J Thorac Oncol 2010 2010 ;5:658-66
Yong-feng Yu, Zhi-wei Chen, Zhen Zhou, Shun Lu （通讯作者） A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexedin Second-line Chemotherapy for Stage III b or IV Non-Small Cell Lung Cancer Patients in China Chemotherapy 2010 2010,56:472-477
JIE ZHANG,NIU Xiao-Min , LIAO Mei-Lin, LU Shun （通讯作者） Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer Oncology reports 2010 2010;24:1185-92
Zhiwei Chen, Yongfeng Yu, Da Fu,Shun Lu （通讯作者） Functional roles of PC-PLC and Cdc20 in the cell cycle,proliferation, and apoptosis Cell Biochem Funct 2010 2010,28, 249 – 257
Li Zi-Ming,Yu Yong-Feng, Lu J, Lu Shun （通讯作者） Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China Journal of Thoracic Oncology 2009 2009 ;4:702-9
ZHANG Yi-fei, CHEN Zhi-wei, Lu Shun （通讯作者） Pemetrexed Monotherapy versus Pemetrexed plus Platinum Combination as Second-line Treatment for Advanced Non-small Cell Lung Cancer Chinese Medical Journal. 2009 2009;122: 2472-2476